Identifying and Exploring the Impact Factors for Intraocular Pressure Prediction in Myopic Children with Atropine

Tzu-En Wu1,2, Jun-Wei Chen3, Tzu-Chi Liu4

  • 1Department of Ophthalmology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei 11101, Taiwan.

PubMed

Insights

Topical atropine for myopia control in children is safe when baseline intraocular pressure (IOP) is below 14 mmHg. Higher baseline IOP may increase IOP with atropine treatment, necessitating careful monitoring.

Area of Science:

  • Ophthalmology
  • Pediatric Medicine
  • Artificial Intelligence in Healthcare

Background:

  • Topical atropine is a common treatment for childhood myopia, effective in slowing its progression.
  • Monitoring intraocular pressure (IOP) is essential for the safe use of atropine.
  • Establishing a precise baseline IOP is crucial for clinical safety assessments.

Purpose of the Study:

  • To identify the optimal machine learning module for monitoring IOP in children treated with atropine.
  • To establish a precise baseline IOP as a clinical safety reference for atropine therapy.

Main Methods:

  • Retrospective analysis of data from 1545 eyes of 1171 children undergoing atropine treatment for myopia.
  • Utilized a multivariate adaptive regression spline (MARS) model to analyze 19 variables affecting End IOP.
  • Key variables included patient demographics, medical history, refractive error, and IOP measurements.

Main Results:

  • The MARS model identified age, baseline IOP, End Spherical, and atropine treatment durations as significant factors influencing End IOP.
  • Baseline IOP was the most influential factor, with a critical threshold identified at 14 mmHg.
  • A positive correlation between atropine use and End IOP was observed when baseline IOP equaled or exceeded 14 mmHg.

Conclusions:

  • The MARS model effectively captures nonlinearity in predicting End IOP compared to traditional linear regression.
  • Atropine administration may increase IOP in children with a baseline IOP exceeding 14 mmHg.
  • Findings provide critical insights for clinicians to optimize atropine therapy and ensure patient safety.
Abstract

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
452
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
573
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
500